ArticleBlood2018
Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Post-translational modification-regulating biomaterials for regeneration.Bioactive materials · 2026Review
- Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB-9778.Pharmacology research & perspectives · 2026Article
- Automated Imaging and Analysis of Platelet, Coagulation and Fibrinolysis Activities Using a Novel Flow Chip-Based System at Physiological Temperature.Micromachines · 2025Article
- BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Article
- Proteomic Analyses of Clots Identify Stroke Etiologies in Patients Undergoing Endovascular Therapy.CNS neuroscience & therapeutics · 2025Article
- Characterisation and hierarchy of the spermatogonial stem cell compartment in human spermatogenesis by spectral cytometry using a 16-colors panel.Cellular and molecular life sciences : CMLS · 2024Article
- LAIR-1 and PECAM-1 function via the same signaling pathway to inhibit GPVI-mediated platelet activation.Research and practice in thrombosis and haemostasis · 2024Article
- Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity.Blood advances · 2023Article
- Regulation, targets and functions of CSK.Frontiers in cell and developmental biology · 2023Review
- Review
- Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.American journal of physiology. Cell physiology · 2022Review
- The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.Blood advances · 2022Article
- Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease.Blood advances · 2022Article
- Lymphatic blood filling in CLEC-2-deficient mouse models.Platelets · 2021Article
- Platelet Src family kinases: A tale of reversible phosphorylation.Research and practice in thrombosis and haemostasis · 2021Review
- Heterozygous mutation SLFN14 K208N in mice mediates species-specific differences in platelet and erythroid lineage commitment.Blood advances · 2021Article
- Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases.International journal of medical sciences · 2021Review
- The (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes.Medicina (Kaunas, Lithuania) · 2020Review
- Loss ofBlood science (Baltimore, Md.) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 4 countries.
Funding
Abstract
Src family kinases (SFKs) coordinate the initiating and propagating activation signals in platelets, but it remains unclear how they are regulated. Here, we show that ablation of C-terminal Src kinase (Csk) and receptor-like protein tyrosine-phosphatase CD148 in mice results in a dramatic increase in platelet SFK activity, demonstrating that these proteins are essential regulators of platelet reactivity. Paradoxically, Csk/CD148-deficient mice exhibit reduced in vivo and ex vivo thrombus formation and increased bleeding following injury rather than a prothrombotic phenotype. This is a consequence of multiple negative feedback mechanisms, including downregulation of the immunoreceptor tyrosine-based activation motif (ITAM)- and hemi-ITAM-containing receptors glycoprotein VI (GPVI)-Fc receptor (FcR) γ-chain and CLEC-2, respectively and upregulation of the immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor G6b-B and its interaction with the tyrosine phosphatases Shp1 and Shp2. Results from an analog-sensitive Csk mouse model demonstrate the unconventional role of SFKs in activating ITIM signaling. This study establishes Csk and CD148 as critical molecular switches controlling the thrombotic and hemostatic capacity of platelets and reveals cell-intrinsic mechanisms that prevent pathological thrombosis from occurring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.